Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Apr 1;22(7):1550-2.
doi: 10.1158/1078-0432.CCR-15-3054. Epub 2016 Feb 3.

Of Mice and Melanoma: PDX System for Modeling Personalized Medicine

Edward J Hartsough  1 , Andrew E Aplin  2
Affiliations
Comment

Of Mice and Melanoma: PDX System for Modeling Personalized Medicine

Edward J Hartsough et al. Clin Cancer Res. .

Abstract

Targeted therapies have advanced the treatment options for cutaneous melanoma, but many patients will progress on drug. Patient-derived xenografts (PDX) can be used to recapitulate therapy-resistant tumors. Furthermore, PDX modeling can be utilized in combination with targeted sequencing and phosphoproteomic platforms, providing preclinical basis for second-line targeted inhibitor strategies. See related article by Krepler et al., p. 1592.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest: A.E. Aplin reports receiving commercial research support from Pfizer. No potential conflicts of interest were disclosed by the other author.

Figures

Figure 1
Figure 1
Schematic workflow depicting the identification of second-line targets from drug-resistant PDXs through next-generation sequencing and RPPA platforms. Resistant PDXs are propagated to be utilized in assays testing the efficacy of therapeutics against potential resistance mechanisms to ultimately inform second-line treatments in resistant melanoma patients.
See this image and copyright information in PMC

Comment on

References

    1. Krepler C, Xiao M, Spoesser K, Brafford PA, Shannan B, Beqiri M, et al. Personalized pre-clinical trials in BRAF inhibitor resistant patient derived xenograft models identify second line combination therapies. Clin Cancer Res. 2015 Dec 16; [Epub ahead of print] - PMC - PubMed
    1. Chan MM, Haydu LE, Menzies AM, Azer MW, Klein O, Lyle M, et al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer. 2014;120:3142–53. - PubMed
    1. Seghers AC, Wilgenhof S, Lebbe C, Neyns B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 2012;22:466–72. - PubMed
    1. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494:251–5. - PMC - PubMed
    1. Hartsough EJ, Basile KJ, Aplin AE. Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res. 2014;12:795–802. - PMC - PubMed

Publication types